M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Swedish Axelar completes phase I/II trial with cancer drug
7 July 2011 - Axelar AB, a portfolio company of Swedish pharma investor Karolinska Development AB (STO: KDEV), said today it has completed a phase I/II trial with its drug candidate AXL1717 in patients with solid tumors.
The preliminary results of this open-label safety study are due to be...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives